TGTX TG Therapeutics, Inc.

+2  (15%)
Previous Close 10.40
Open 10.80
Price To book 16.46
Market Cap 681.35M
Shares 56,779,000
Volume 3,744,258
Short Ratio 1.95
Av. Daily Volume 2,241,200

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 initiated October 2016.
Relapsed or refractory lymphoma - cancer
Phase 2 preliminary results to be presented at American Academy of Neurology (AAN) annual meeting April 28, 2017.
Multiple Sclerosis
Phase 2b enrollment commenced June 2016. First interim analysis due mid-2017.
TG-1101 and TGR-1202 - UNITY-DLBCL study
Diffuse large B-cell lymphoma (DLBCL) cancer
Phase 3 trial met primary endpoint - March 6, 2017, meeting with FDA in 2H 2017.
TG-1101 and IMBRUVICA (GENUINE trial)
Chronic Lymphocytic Leukemia (CLL) cancer
Phase 3 enrollment to be completed 1Q 2018.
TG-1101 and TGR-1202 - UNITY-CLL study
Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)

Latest News

  1. Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and TG Therapeutics
  2. Why TG Therapeutics Inc. Jumped Higher Today
  3. Potential FDA Controversy Brewing For TG Therapeutics?
  4. TG Therapeutics, Inc. Recaps Schedule of Data Presentation at the Upcoming American Academy of Neurology 69th Annual Meeting
  5. Physician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics
  6. If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss
  7. TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
  8. FDA Drug Approvals on the Rise in 2017: Today's Research Reports on Sarepta Therapeutics and TG Therapeutics
  9. Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock?
  10. TG Therapeutics stock rises 2% on preclinical data for cancer drug
  11. TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting
  12. 3 Top Biotech Stocks to Buy in April
  13. 5 Top Performing Stocks of the Best ETF of Q1
  14. ETFs with exposure to TG Therapeutics, Inc. : March 27, 2017
  15. TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017
  16. TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting
  17. TG Therapeutics, Inc. to Present at the 27th Annual Oppenheimer Healthcare Conference
  18. TG Therapeutics and ImmunoGen are Models of Institutional Investor Attention
  19. TG Therapeutics, Inc. to Present at the 29th Annual ROTH Conference